Best GLP-1 for Perimenopause & Menopause

The weight-gain pattern women experience during perimenopause and menopause is biologically different from weight gain in your 20s or 30s. Estrogen levels fluctuate wildly and eventually decline, driving three specific changes:

• Fat redistribution. Fat moves from hips and thighs to the abdomen. Visceral fat (the metabolically dangerous kind) increases disproportionately.
• Muscle loss acceleration. Estrogen supports muscle protein synthesis. Its decline accelerates sarcopenia, which lowers resting metabolic rate.
• Insulin resistance development. Many perimenopausal and menopausal women develop new or worsening insulin resistance, even without significant weight gain.

GLP-1 medications are a particularly good match for this picture. They address insulin resistance directly, reduce appetite (which often increases due to fluctuating hormone signals), and when combined with resistance training can help preserve muscle during weight loss. Studies suggest semaglutide and tirzepatide are as effective in postmenopausal women as in premenopausal women — but the care context around the medication matters more at this life stage.

What matters for perimenopausal and menopausal patients on GLP-1s

• HRT coordination. If you're on (or considering) hormone replacement therapy, you need a provider who can coordinate GLP-1 with estrogen and potentially testosterone therapy — not treat them as unrelated.
• Muscle preservation emphasis. Postmenopausal women lose muscle at 1–2% per year. Rapid GLP-1 weight loss without resistance training and adequate protein compounds the problem.
• Bone health awareness. Rapid weight loss can accelerate bone density loss. Providers should discuss calcium, vitamin D, and weight-bearing exercise.
• Slower titration. Menopause often comes with more GI sensitivity. Going up in dose more gradually reduces nausea and dropout.
• Thyroid coordination. Hypothyroidism rates rise in postmenopausal women. Labs should include TSH at baseline.

Our rankings

The HRT coordination question

Here's an important clinical consideration: GLP-1 medications can alter the absorption of oral medications taken at the same time, including oral estrogen. This isn't a contraindication — plenty of women successfully combine HRT and GLP-1 — but timing and formulation choices matter.

• Oral estrogen: Take at a different time of day than oral GLP-1 (Rybelsus, oral Wegovy, compounded oral), ideally 2+ hours apart.
• Transdermal estrogen (patches, gels, creams): No absorption interaction with GLP-1 medications. This is the preferred format for women on oral GLP-1.
• Injectable semaglutide/tirzepatide: No significant absorption interaction with most HRT formats, making timing less critical.

Any HRT-coordinating provider should discuss these timing considerations. If yours doesn't, ask directly.

Muscle preservation: the menopause-specific urgency

What about perimenopause specifically?

Perimenopause — the 4–10 year transition before menopause itself — has its own challenges. Estrogen levels fluctuate wildly rather than steadily declining, which can produce weight changes, sleep disruption, and mood swings. Some perimenopausal women gain 10–15 pounds over a few years without changing their diet or exercise habits.

GLP-1 medications work the same way in perimenopause as in menopause, but a few additional considerations:

• Cycle tracking still matters. Some perimenopausal women are still ovulating, so contraception considerations apply if not actively trying to conceive. GLP-1s are contraindicated in pregnancy.
• Hormonal fluctuation can amplify side effects. What feels manageable one week can feel worse the next. Slower titration is often better.
• HRT decisions may be pending. If you're still deciding on HRT, a provider who can discuss both hormone therapy and GLP-1 together is valuable.

Questions to ask your provider during intake

• "I'm perimenopausal/menopausal. How does that affect my treatment plan?"
• "I'm considering / on HRT. Can you coordinate with my prescriber?"
• "What baseline labs do you recommend? (Should include TSH, A1C, lipid panel, vitamin D)"
• "What's your approach to muscle preservation during GLP-1 weight loss?"
• "If I experience increased GI sensitivity, can we slow the titration?"
• "How do you think about bone health during rapid weight loss at this life stage?"

A note on the Mochi Health ecosystem

The long-term sustainability question

One concern specific to menopausal weight loss: what happens when you stop the medication? Research on GLP-1 discontinuation shows significant weight regain in most patients within 12 months. For postmenopausal women, the hormonal environment that drove weight gain in the first place hasn't changed — so regain is likely without continued medication or substantial lifestyle intervention.

This argues for two strategic approaches:

1. Plan for long-term use. Budget and commit to GLP-1 as chronic medication, similar to how you'd budget for blood pressure or thyroid medication.
2. Invest heavily in strength training and dietary habits during the weight-loss phase so that if you do come off medication, you've built the habits and muscle mass to defend the loss.

Bottom line

Perimenopausal and menopausal weight changes are a legitimate clinical concern deserving legitimate clinical treatment. GLP-1 medications can be transformative for this population — but the provider you choose matters more than the medication itself. Pick a platform that understands hormone coordination, muscle preservation, and bone health. Treat GLP-1 as one tool in a broader menopause strategy, not a standalone fix. And don't settle for a provider who treats you like a generic weight-loss customer.